Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Merck opens first climate-neutral manufacturing facility in Ireland
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Cagrilintide represents a novel approach to obesity management
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
Subscribe To Our Newsletter & Stay Updated